Enhancing ribociclib administration in patients with breast cancer and brain metastases through a physiologically based pharmacokinetic approach - Takeaways - MDSpire

Enhancing ribociclib administration in patients with breast cancer and brain metastases through a physiologically based pharmacokinetic approach

  • By

  • Chao Zhang

  • Shan Li

  • Jiawei Ren

  • Xiaohui Wen

  • January 13, 2026

  • 0 min

Share

  • 1

    Breast cancer is the most common cancer in women, with significant mortality and a rising incidence, particularly due to brain metastases.

  • 2

    Ribociclib is an effective CDK4/6 inhibitor for HR+/HER2− breast cancer, improving progression-free survival when combined with endocrine therapy.

  • 3

    The blood-brain barrier limits ribociclib delivery to brain metastases, making cerebrospinal fluid drug concentrations critical for treatment efficacy.

  • 4

    Physiologically based pharmacokinetic modeling can optimize ribociclib dosing by predicting its plasma and intracranial pharmacokinetics and target occupancy.

  • 5

    The study aims to develop a population PBPK model to enhance ribociclib administration for patients with breast cancer and brain metastases.

Original Source(s)

Enhancing ribociclib administration in patients with breast cancer and brain metastases through a physiologically based pharmacokinetic approach

  • by Chao Zhang, Shan Li, Jiawei Ren, Xiaohui Wen

  • January 13, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer